Skip to main content

Pierre Massion, M.D.

  • Co-Leader, Cancer Health Outcomes and Control Research Program
  • Cornelius Vanderbilt Professor of Medicine
  • Director, Cancer Early Detection and Prevention Initiative

Phone

615-322-3412

Email

pierre.massion@Vanderbilt.Edu
Vanderbilt University Medical Center
Vanderbilt-Ingram Cancer Center PRB 640
2220 Pierce Avenue
Nashville, TN 37232

Pierre Massion, M.D.

  • Co-Leader, Cancer Health Outcomes and Control Research Program
  • Cornelius Vanderbilt Professor of Medicine
  • Director, Cancer Early Detection and Prevention Initiative

615-322-3412

pierre.massion@Vanderbilt.Edu

Vanderbilt University Medical Center
Vanderbilt-Ingram Cancer Center PRB 640
2220 Pierce Avenue
Nashville, TN 37232

Profile

Dr. Pierre Massion is the Ingram Professor of Cancer Research and Professor of Medicine in the Division of Allergy, Pulmonary and Critical Care Medicine at Vanderbilt Medical Center. Dr. Massion has worked in the field of lung cancer biology, early detection and therapeutics for 16 years. He is the director of the Thoracic Program at the Vanderbilt Ingram Cancer Center and thereby overseeing and fostering a rich environment to translate science from the program to trials in the cooperative groups. He has over 80 publications in the areas of lung cancer development, role of oncogenes in the progression of lung tumor cells and innovative strategies towards the development of molecular biomarkers for early detection of lung cancer and intermediate endpoint biomarkers of response to chemoprevention. He served as Chief of the Pulmonary and Critical Care Medicine section at the Nashville VA Medical Center between 2007-2012. He is certified by the American Board of Internal Medicine in Internal Medicine and in Pulmonary and Critical Care Medicine. He is the principal investigator of the Vanderbilt SPORE in lung cancer and of the Vanderbilt Clinical Validation Center sponsored by the EDRN to validate candidate biomarkers of lung cancer. He is also co-PI of two DoD grants, one of which offers lung cancer screening across 12 VA and military hospitals to validate candidate biomarkers of risk and of diagnosis for lung cancer. Dr. Massion has mentored over 19 postdoctoral fellows, 11 graduate students and 20 undergraduate students. He is committed to pursuing innovative strategies to deepen the understanding of lung cancer development and progression. His laboratory applies novel genomic and proteomic technologies to biological specimens to address questions related to the identification and validation of molecular determinants of disease diagnosis, progression, prognosis, and intermediate endpoint biomarkers of response to chemopreventive strategies. He is the PI of 6 active clinical studies - http://www.clinicaltrials.gov. He is the Chair of the Lung Cancer Cooperative group in the EDRN and the Chair of the Scientific Advisory Board of the largest non-profit lung cancer foundation LUNGevity. He is a contributing member to the National Comprehensive Cancer Network related Non-Small Cell Lung Cancer Guidelines committee.

Education

  • M.D., Catholic University of Louvain, Louvain, Belgium (1987)
  • B.S., Catholic University of Louvain, Louvain, Belgium (1983)

Postgraduate Training

  • Fellowship - University of California San Francisco Medical Center
  • Internship - Saint Luc Hospital
  • Post Graduate Training - Catholic University of Louvain
  • Post Graduate Training - University of California San Francisco Medical Center
  • Residency - University of California San Francisco Medical Center

Research Emphasis

The laboratory of Dr. Massion emphasis is on lung tumorigenesis and on using molecular and structural imaging approaches to identify markers of lung neoplasia and to test those in multidisciplinary early detection strategies.

Research Description


The goal of my laboratory is to deepen our understanding of the molecular determinants lung cancer development. Our translational research is dedicated to answering significant questions including the following: Who among high-risk individuals develop lung cancer? What cell subtype carries the risk over time? How do preinvasive lung lesions escape the immune response in the airways? What are the oncogenic drivers of the chromosome 3q amplicon? How does metabolic reprogramming in the high risk airway epithelium contribute to genomic instability? What metabolic vulnerabilities could be explored in chemoprevention? And on a more translational goal, how do we develop non-invasive strategies to detect lung cancer early? We integrate clinical predictors, protein biomarkers, structural imaging and molecular imaging markers to distinguish benign from malignant lung nodules.

Publications

Have any questions? Contact Us 1-877-936-8422 for more information